USPTO published a patent application (US20260094684A1) for a method of assessing the effectiveness of psychotropic drugs using pupillary biomarkers. The method involves obtaining pupillary data from a subject before and after drug administration using a pupilometer, processing the data, and displaying an output indicating effectiveness. CPC Classifications include G16H 20/10 (ICT for pharmaceuticals), A61B 3/112 (pupillometers), and A61B 3/14 (eye examination devices). The application was filed on 2024-09-27.

This patent application does not create regulatory obligations for pharmaceutical manufacturers or healthcare providers. It is informational, indicating that a method for assessing psychotropic drug effectiveness via pupillary biomarkers has been invented and published. Companies developing psychotropic medications or pupilometer devices may wish to review this application to assess potential patent landscape implications. No compliance deadlines or penalties are associated with this publication.